congresses-banner

The content contained is subject

PublicationView

Poster
Quizartinib
EHA 2024 | June 13-16, 2024
Hematology
QuANTUM-First: Efficacy by age in newly diagnosed patients with FMS-like tyrosine kinase 3-internal tandem duplication–positive acute myeloid leukemia
Pau Montesinos
Oral
Quizartinib
EHA 2024 | June 13-16, 2024
Hematology
QuANTUM-First: Efficacy in newly diagnosed patients with FMS-like tyrosine kinase 3-internal tandem duplication–positive acute myeloid leukemia who received continuation therapy
Mikkael A. Sekeres
Poster
Quizartinib
EHA 2024 | June 13-16, 2024
Hematology
QuANTUM-First: Patient-reported outcomes in newly diagnosed Italicize FLT3-ITD+ acute myeloid leukemia patients receiving standard chemotherapy plus quizartinib or placebo
Esther Natalie Oliva
Oral
Valemetostat
EHA 2024 | June 13-16, 2024
Other/Multi-Tumor
Valemetostat monotherapy in patients with relapsed or refractory peripheral T-cell lymphomas: Efficacy by prior lines of treatment and last treatment outcome from the VALENTINE-PTCL01 study
Pier Luigi Zinzani
Poster
Valemetostat
EHA 2024 | June 13-16, 2024
Other/Multi-Tumor
Valemetostat monotherapy in relapsed or refractory non-hodgkin lymphomas: A first-in-human phase 1 clinical trial
Dai Maruyama

footer